RedHill and U.S. Army Announce Opaganib ' s Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study

TEL AVIV, Israel and RALEIGH, NC, Oct. 3, 2023. RedHill Biopharma Ltd. ( " RedHill " or the " Company " ), a specialty biopharmaceutical company, today announced that novel, twice daily, oral opaganib[1], delivered a statistically significant increase in...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials